Correction

Published on 25 Nov 2024

Corrigendum: Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell

in Pharmacology of Anti-Cancer Drugs

Junyi Chen
Fubo Wang
Huan Xu
Lingfan Xu
Dong Chen
Jialiang Wang
Sihuai Huang
Yiqun Wen
Longmin Fang

Frontiers in Oncology

doi 10.3389/fonc.2024.1501882

Review

Published on 25 Nov 2024

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

in Pharmacology of Anti-Cancer Drugs

Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1481777

Review

Accepted on 22 Nov 2024

The Antitumor Mechanisms of Glabridin and Drug Delivery Strategies for Enhancing Its Bioavailability

in Pharmacology of Anti-Cancer Drugs

Chong Li
Yu Wang
Wen Jing Zhang
Xiaoman Yang
Yufang Wang
Guanqun Hou
Dongli Wang
Bingbing Han
Yimin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1506588

Case Report

Published on 20 Nov 2024

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma

in Pharmacology of Anti-Cancer Drugs

Luigia Turco
Rosa Della Monica
Pasqualina Giordano
Mariella Cuomo
Manuele Biazzo
Baptiste Mateu
Raimondo Di Liello
Bruno Daniele
Nicola Normanno
Antonella De Luca

Frontiers in Oncology

doi 10.3389/fonc.2024.1458990

192 views

Original Research

Accepted on 19 Nov 2024

Cutaneous adverse events due to Checkpoint inhibitors – A retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022.

in Pharmacology of Anti-Cancer Drugs

Clara Theresa Furrer-Matcau
Chloé Sieber
Dirk Lehnick
Christoph Urs Brand
Balthasar Hug

Frontiers in Oncology

doi 10.3389/fonc.2024.1485594

Editorial

Accepted on 18 Nov 2024

Editorial: Photodynamic Therapy: Challenges and Innovations for Treating Cancer

in Pharmacology of Anti-Cancer Drugs

Newton Soares Da Silva
Juliana Ferreira-Strixino
Cristina Pacheco-Soares

Frontiers in Oncology

doi 10.3389/fonc.2024.1526550

Editorial

Accepted on 18 Nov 2024

Editorial: DNA Methylation in Cancer Therapy: Therapeutic Targets and Molecular Mechanism

in Pharmacology of Anti-Cancer Drugs

Guoyi Yan
Shaofeng Duan
Jinyang Cai

Frontiers in Oncology

doi 10.3389/fonc.2024.1508214

Correction

Accepted on 18 Nov 2024

Corrigendum: Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling

in Pharmacology of Anti-Cancer Drugs

JiaHui Wu
Xiao He
Ziwei Xiong
Lingyu Shi
Daofeng Chen
Yulin Feng
Quan Wen

Frontiers in Oncology

doi 10.3389/fonc.2024.1515205

Review

Published on 12 Nov 2024

Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects

in Pharmacology of Anti-Cancer Drugs

Parminder Kaur
Pankaj Sharma
Prateek Bhatia
Minu Singh

Frontiers in Oncology

doi 10.3389/fonc.2024.1445794

223 views

Original Research

Published on 08 Nov 2024

Mechanism of luteolin against non-small-cell lung cancer: a study based on network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments

in Pharmacology of Anti-Cancer Drugs

Jihang Zhang
Changling Li
Wenyi Li
Zhenpeng Shi
Zhenguo Liu
Junyu Zhou
Jing Tang
Zixuan Ren
Yun Qiao
Deshan Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1471109

265 views

Correction

Accepted on 31 Oct 2024

A Corrigendum on Chamaejasmin B Decreases Malignant Characteristics of Mouse Melanoma B16F0 and B16F10 Cells

in Pharmacology of Anti-Cancer Drugs

Lingling Si
Qiusheng Zheng

Frontiers in Oncology

doi 10.3389/fonc.2024.1472829

Original Research

Accepted on 30 Oct 2024

Pembrolizumab versus Sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis

in Pharmacology of Anti-Cancer Drugs

Zhengzheng Xia
Zhuoshi Lian
Huali Xie
Ziyuan Zhou
Tujia Chen
Jun Meng
Jun Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1422039

Correction

Published on 28 Oct 2024

Corrigendum: Dietary polyphenols, resveratrol and pterostilbene exhibit antitumor activity on an HPV E6-positive cervical cancer model: an in vitro and in vivo analysis

in Pharmacology of Anti-Cancer Drugs

Kaushiki Chatterjee
Sumit Mukherjee
Jonathan Vanmanen
Probal Banerjee
Jimmie E. Fata

Frontiers in Oncology

doi 10.3389/fonc.2024.1483410

240 views

Review

Published on 23 Oct 2024

Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?

in Pharmacology of Anti-Cancer Drugs

Shadiya Fawzul Ameer
Muna Yusuf Mohamed
Qubaa Ahmed Elzubair
Elham Abdullatif M. Sharif
Wisam Nabeel Ibrahim

Frontiers in Oncology

doi 10.3389/fonc.2024.1438040

727 views

Editorial

Published on 18 Oct 2024

Editorial: Novel drug discovery and design in acute myeloid leukemia: from bench to bedside

in Pharmacology of Anti-Cancer Drugs

Yan-Lai Tang
Zhenhua Chen
Xue-Qun Luo

Frontiers in Oncology

doi 10.3389/fonc.2024.1449636

475 views

Original Research

Published on 18 Oct 2024

Identification and validation of matrix metalloproteinase hub genes as potential biomarkers for Skin Cutaneous Melanoma

in Pharmacology of Anti-Cancer Drugs

Zhongyi Zhang
Mei Zhao
Zubing Zhou
Xiaodan Ren
Yunliang He
Tao Shen
Hongping Zeng

Frontiers in Oncology

doi 10.3389/fonc.2024.1471267

567 views

Navigation group

Articles

Corrigendum: Long non-coding RNA SNHG1 regulates the Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways via EZH2 to affect the proliferation, apoptosis, and autophagy of prostate cancer cell

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

The Antitumor Mechanisms of Glabridin and Drug Delivery Strategies for Enhancing Its Bioavailability

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion–positive glioblastoma

Cutaneous adverse events due to Checkpoint inhibitors – A retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022.

Editorial: Photodynamic Therapy: Challenges and Innovations for Treating Cancer

Editorial: DNA Methylation in Cancer Therapy: Therapeutic Targets and Molecular Mechanism

Corrigendum: Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling

Current insights on m6A RNA modification in acute leukemia: therapeutic targets and future prospects

Mechanism of luteolin against non-small-cell lung cancer: a study based on network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments

A Corrigendum on Chamaejasmin B Decreases Malignant Characteristics of Mouse Melanoma B16F0 and B16F10 Cells

Pembrolizumab versus Sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis

Corrigendum: Dietary polyphenols, resveratrol and pterostilbene exhibit antitumor activity on an HPV E6-positive cervical cancer model: an in vitro and in vivo analysis

Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?

Editorial: Novel drug discovery and design in acute myeloid leukemia: from bench to bedside

Identification and validation of matrix metalloproteinase hub genes as potential biomarkers for Skin Cutaneous Melanoma